Class of 2025
For instrumental advancements to cancer drug development, including the discovery of the HSP90 inhibitor NVP-AUY922 (luminespib), the PI3K inhibitor GDC-0941 (pictilisib), the AKT inhibitor AZD5363 (capivasertib), and the EGFR inhibitor ZD 1839 (gefitinib); and for conceptualizing the “Pharmacological Audit Trail,” a biomarker-driven framework that has revolutionized rational decision-making in the establishment of oncology therapeutics.
*Full-length biography in development